Adverse effects of biologics: a network meta-analysis and Cochrane overview.

By J. Singh, G. Wells, R. Christensen, Elizabeth Tanjong Ghogomu, L. Maxwell, J. Macdonald, G. Filippini, N. Skoetz, Damian K. Francis, L. Lopes and 10 more. Cochrane Database of Systematic Reviews, 2011

952 citations recorded by the source corpus.

Subfields: Rheumatology, Toxicology

View Paper: https://www.semanticscholar.org/paper/7125b472d91cc607bfd07898cbf33edc17c07c18

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Teachey
2. S. Maude
3. S. Grupp
4. D. Barrett
5. Jennifer N. Brudno
6. J. Kochenderfer

Citations in the corpus

• Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies (2014, background): “Tocilizumab, a recombinant humanized monoclonal antibody against the IL-6 receptor, blocks IL-6 from binding to its receptor, both in membrane-bound and soluble states.(26,27) With a primary indication for juvenile idiopathic arthritis (JIA), tocilizumab is approved by the Food and Drug Administrati”
• TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. (2014, neutral): “studies with 11,954 patients, concluded that the rate of lymphoma, and congestive heart failure, were not statistically significant [252].”